DNAnexus is a technology company.
DNAnexus has raised $458.0M across 7 funding rounds.
DNAnexus has raised $458.0M in total across 7 funding rounds.
DNAnexus has raised $458.0M in total across 7 funding rounds.
DNAnexus's investors include aMoon Fund, Echo Health Ventures, Foresite Capital, GV, Khosla Ventures, Kleiner Perkins, Northpond Ventures, venBio, Yumin Choi, Anorak Ventures, Baseline Ventures, First Round Capital.
DNAnexus is a technology company providing a secure, scalable cloud platform for precision health, specializing in bioinformatics and multi-omics data management.[1][2][6] It builds products like Apollo (for multi-omics analysis and collaboration to accelerate drug discovery) and Titan (for high-throughput genomic data processing to identify variants and build large datasets), serving biopharma, biotech, clinical diagnostics, academic medical centers, biobanks, population health programs, and real-world data aggregators.[2][4][6] The platform solves the challenge of handling massive, complex datasets—such as over 125 petabytes of clinical, genomic, proteomic, and multi-omic data—enabling faster analysis, secure collaboration, and insights for personalized treatments amid exploding genome sequencing volumes (projected at 500 million genomes or 40 exabytes by 2025).[1][4][5] With strong growth momentum, including a $200M financing round, over 60,000 users across 48 countries, and recent launches like a GenAI-powered Omics Data Assistant, DNAnexus accelerates precision medicine workflows.[4][5]
DNAnexus was founded in 2009 in Mountain View, California, amid the explosion of genome sequencing data volumes and rapidly declining costs, addressing the need for scalable cloud computing and bioinformatics at extreme scale.[1][2] The founders leveraged expertise in science, engineering, cloud technology, and compliance to create a platform that evolved from genomics to multi-omics and beyond, establishing leadership by 2013 through partnerships with pharmaceutical companies, biotechs, healthcare providers, and academics.[1] Key pivotal moments include strategic alliances for DNA-based medicine advancement, a $200M funding round to fuel product roadmaps, and recent leadership hires to drive AI innovation and biopharma expansion, building on 15+ years of bioinformatics innovation.[4][5][7]
DNAnexus rides the precision health wave, fueled by advancements in multi-omics, single-cell, imaging tech, and AI, where only a fraction of 40 exabytes of sequencing data is currently leveraged for drug discovery.[4][5] Timing is ideal as costs drop and data explodes, enabling biopharma to correlate genomic/phenotypic insights for faster target ID, biomarkers, and therapies amid regulatory demands for secure, compliant solutions.[1][6][9] Market forces like rising demand for real-world data harmonization and collaborative ecosystems favor its global network, influencing the landscape by powering breakthroughs in personalized medicine, regulatory science, and population health for 60,000+ users.[3][5][6]
DNAnexus is poised to expand its AI-driven tools and biopharma alliances, scaling peta-scale infrastructure to integrate next-gen multi-modal data and accelerate treatments.[5] Trends like GenAI for non-experts, real-world evidence demands, and 500M+ genomes will propel growth, potentially evolving its influence through deeper ecosystem partnerships and regulatory solutions. As the enterprise backbone for precision health, it ties back to its 2009 roots—unlocking data's power to transform human health.
DNAnexus has raised $458.0M across 7 funding rounds. Most recently, it raised $200.0M Series H in March 2022.